Lipiodol Retention Pattern After TACE for HCC is a Predictor for Local Progression in Lesions with Complete Response

Overview

Journal Cancer Imaging

Publisher Springer Nature

Specialties Oncology
Radiology

Date 2019 Nov 16

PMID 31730491

Citations 22

Authors

Marco Dioguardi Burgio

Riccardo Sartoris

Claudia Libotean

Magaly Zappa

Annie Sibert

Valerie Vilgrain

Maxime Ronot

Affiliations

Soon will be listed here.

Abstract

Background: To evaluate the predictive value of the lipiodol retention pattern for local progression of HCC with a complete response (CR) on CT according to mRECIST criteria after a first session of conventional chemoembolization (cTACE).

Methods: From January 2014 to May 2016 all consecutive patients undergoing a first cTACE session for HCC were identified. Inclusion criteria were the presence of ≤3 HCCs and available pre- and post-cTACE CT. Tumor response was classified according to mRECIST criteria. The analysis focused on tumors with a CR. The lipiodol retention pattern in these tumors was classified as complete (C-Lip, covering the entire tumor volume), or incomplete (I-Lip). Local progression was defined as the reappearance of areas of enhancement on arterial-phase images with washout on portal/delayed phase images within 2 cm from treated tumors on follow-up CT.

Results: The final population included 50 patients with 82 HCCs. A total of 46 (56%) HCCs were classified with a CR, including 16 (35%) with I-Lip, and 30 (65%) with C-Lip. After a median follow-up of 14 months (3.2-35.9 months), 15/16 (94%) and 10/30 (30%) of I-Lip and C-Lip HCCs showed local progression on CT, respectively (p < 0.001), with no significant difference in the time to progression (mean 11.1 ± 2 vs. 13.4 ± 3 months for I-Lip and C-Lip, respectively p = 0.51).

Conclusions: HCCs with incomplete lipiodol retention after a first cTACE session have a high risk of local progression even when there is a CR according to mRECIST, and should be considered to be incompletely treated.

Citing Articles

Complete contrast staining of hepatocellular carcinoma during drug-eluting bead chemoembolization predicts a favorable response.

Alharbi S J Clin Imaging Sci. 2024; 14:46.

PMID: 39639882 PMC: 11618748. DOI: 10.25259/JCIS_129_2024.

Lipiodol accumulation patterns and their impact on survival outcomes in transarterial chemoembolization for hepatocellular carcinoma: a single institution retrospective analysis.

Bannangkoon K, Hongsakul K, Tubtawee T Sci Rep. 2024; 14(1):18979.

PMID: 39152197 PMC: 11329683. DOI: 10.1038/s41598-024-69993-1.

Benign and malignant focal liver lesions displaying rim arterial phase hyperenhancement on CT and MRI.

Matteini F, Cannella R, Garzelli L, Dioguardi Burgio M, Sartoris R, Brancatelli G Insights Imaging. 2024; 15(1):178.

PMID: 39020233 PMC: 11254889. DOI: 10.1186/s13244-024-01756-y.

Clinical impact and potential utility of non-enhanced computed tomography performed immediately after transarterial chemoembolization for hepatocellular carcinoma.

Kim M, Heo S, Choi S, Suh C, Lee E, Park H J Gastrointest Oncol. 2024; 15(3):1141-1152.

PMID: 38989419 PMC: 11231851. DOI: 10.21037/jgo-24-134.

Hepatocellular Carcinoma: Optimal Radiological Evaluation before Liver Transplantation.

Dioguardi Burgio M, Garzelli L, Cannella R, Ronot M, Vilgrain V Life (Basel). 2023; 13(12).

PMID: 38137868 PMC: 10744421. DOI: 10.3390/life13122267.

References

Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton M . MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2009; 33(3):532-40. DOI: 10.1007/s00270-009-9728-y. View

Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs A . EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011; 55(6):1309-16. DOI: 10.1016/j.jhep.2011.03.007. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Millonig G, Graziadei I, Freund M, Jaschke W, Stadlmann S, Ladurner R . Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2007; 13(2):272-9. DOI: 10.1002/lt.21033. View

Vogl T, Trapp M, Schroeder H, Mack M, Schuster A, Schmitt J . Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology. 2000; 214(2):349-57. DOI: 10.1148/radiology.214.2.r00fe06349. View

Georgiades C, Geschwind J, Harrison N, Hines-Peralta A, Liapi E, Hong K . Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?. Radiology. 2012; 265(1):115-23. PMC: 4137783. DOI: 10.1148/radiol.12112264. View

Hunt S, Yu W, Weintraub J, Prince M, Kothary N . Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation. J Vasc Interv Radiol. 2008; 20(1):30-8. DOI: 10.1016/j.jvir.2008.09.034. View

Facciorusso A, Bellanti F, Villani R, Salvatore V, Muscatiello N, Piscaglia F . Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials. United European Gastroenterol J. 2017; 5(4):511-518. PMC: 5446148. DOI: 10.1177/2050640616673516. View

Shim J, Han S, Shin Y, Yu E, Park W, Kim K . Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria. J Vasc Interv Radiol. 2013; 24(3):316-25. DOI: 10.1016/j.jvir.2012.10.022. View

10.

Kim B, Kim S, Kim K, Chung Y, Kim M, Park M . Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol. 2015; 62(6):1304-10. DOI: 10.1016/j.jhep.2015.01.022. View

11.

Yu J . Hepatocellular carcinoma after transcatheter arterial chemoembolization: difficulties on imaging follow-up. Korean J Radiol. 2005; 6(3):134-5. PMC: 2685035. DOI: 10.3348/kjr.2005.6.3.134. View

12.

Takayasu K, Arii S, Matsuo N, Yoshikawa M, Ryu M, Takasaki K . Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol. 2000; 175(3):699-704. DOI: 10.2214/ajr.175.3.1750699. View

13.

Kim D, Ryu H, Choi J, Park J, Lee D, Kim B . Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther. 2012; 35(11):1343-50. DOI: 10.1111/j.1365-2036.2012.05089.x. View

14.

Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View

15.

Dioguardi Burgio M, Ronot M, Bruno O, Francoz C, Paradis V, Castera L . Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation. Liver Transpl. 2016; 22(11):1491-1500. DOI: 10.1002/lt.24615. View

16.

Schima W, Ba-Ssalamah A, Kurtaran A, Schindl M, Gruenberger T . Post-treatment imaging of liver tumours. Cancer Imaging. 2007; 7 Spec No A:S28-36. PMC: 2727978. DOI: 10.1102/1470-7330.2007.9047. View

17.

Kinugasa H, Nouso K, Takeuchi Y, Yasunaka T, Onishi H, Nakamura S . Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma. J Gastroenterol. 2011; 47(4):421-6. DOI: 10.1007/s00535-011-0492-9. View

18.

Bargellini I, Bozzi E, Campani D, Carrai P, De Simone P, Pollina L . Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol. 2013; 82(5):e212-8. DOI: 10.1016/j.ejrad.2012.12.009. View

19.

. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019. View

20.

Forner A, Ayuso C, Varela M, Rimola J, Hessheimer A, Rodriguez de Lope C . Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. Cancer. 2009; 115(3):616-23. DOI: 10.1002/cncr.24050. View